AI Article Synopsis

Article Abstract

Introduction: Acute myocardial infarct/angina (AMI-A) is a possible complication in primary antiphospholipid syndrome (pAPS) patients. This study compares data obtained from pAPS patients with and without AMI-A.

Methods: This cross-sectional study of 66 (85.2% female) pAPS patients (Sidney criteria). Demographics, clinical data, medication use, and antiphospholipid antibodies were evaluated. Patients were divided into two groups: pAPS with AMI-A and pAPS without AMI-A.

Results: Sixty-six patients with primary APS (six with AMI-A and 60 without AMI-A) were selected. They were similar for demographics, disease duration, and anthropometrics (p > 0.05). Patients with AMI-A compared to those patients without AMI-A had more frequently dyslipidemia (66 vs. 28%, p = 0.05), systemic hypertension (83 vs. 37%, p = 0.02), and increased levels of lipoprotein (a) (116 ± 67 vs. 36 ± 35 mg/dl, p = 0.0002). Interesting, current physical activity (66.7 vs. 23%, p = 0.04) was more seen in the first group when compared to the second one. Patients with AMI-A used more statins (66 vs. 22%, p = 0.017) and acetylsalicylic (100 vs. 28%, p = 0.05). Higher median levels of IgM anticardiolipin antibodies [70 (0-120) vs. 9 (0-120), p = 0.03] were observed in the first group.

Conclusions: pAPS patients and AMI-A have distinct clinical and laboratory spectra from those without AMI-A. It is characterized by dyslipidemia and hypertension, hyper lipoprotein(a), and a lower IgM anticardiolipin frequency.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964883PMC
http://dx.doi.org/10.1007/s40744-021-00419-4DOI Listing

Publication Analysis

Top Keywords

paps patients
16
patients ami-a
16
ami-a
9
patients
9
primary antiphospholipid
8
antiphospholipid syndrome
8
acute myocardial
8
cross-sectional study
8
28% p = 005
8
igm anticardiolipin
8

Similar Publications

Background: Arrhythmias originating from papillary muscles (PAPs) can be challenging when targeted with catheter ablation. The prevalence and impact of structural abnormalities on PAPs in patients with focal PAP arrhythmias is unknown.

Objectives: The purpose of this study was to analyze, in a consecutive patient series with focal PAP arrhythmias, the impact of structural abnormalities detected by multimodality imaging.

View Article and Find Full Text PDF

Objectives: The 2023 ACR/EULAR antiphospholipid syndrome (APS) classification criteria distinguish between anticardiolipin (aCL) or anti-β2-glycoprotein I (aβ2GPI) IgG vs IgM isotypes, having isolate IgM positivity a low weight, insufficient for APS classification, and define aCL and aβ2GPI thresholds based on fixed cut-off values. We aimed to assess the performance of the 2023 ACR/EULAR criteria in a cohort of primary vascular APS patients (PAPS), previously classified according to the Sydney criteria. Additionally, we evaluated the risk of thrombotic recurrence in patients re-classified or not according to the new criteria.

View Article and Find Full Text PDF

Purpose: To perform a quantitative multimodal evaluation in 25 patients with primary antiphospholipid syndrome (PAPS) without ocular complaints and to compare them with 25 healthy individuals.

Methods: A structural and functional ophthalmological evaluation using optical coherence tomography angiography (OCTA) and microperimetry (MP) exam in 25 patients with PAPS, followed at a tertiary rheumatology outpatient clinic, was performed. All ophthalmologic manifestations were documented and subsequent statistical analysis was performed for comparative purposes, with significance set at < 0.

View Article and Find Full Text PDF

Anti-vitamin D antibodies.

Autoimmun Rev

January 2025

Reichman University, Herzelia, Israel; Zabludowicz Center for Autoimmune Diseases (Founder), Sheba Medical Center, Tel-Hashomer, Israel.

Background: Low vitamin D levels are commonly observed in autoimmune diseases, suggesting a potential role in disease pathogenesis. The presence of anti-vitamin D antibodies may contribute to these deficiencies and influence autoimmune processes.

Objective: To review and analyze studies investigating the occurrence of anti-vitamin D antibodies in autoimmune diseases.

View Article and Find Full Text PDF
Article Synopsis
  • Canadian oncology patients often use patient assistance programs (PAPs) to access oncology drugs while waiting for funding, even within a universal healthcare system.
  • A study reviewed the outcomes of 1,025 patients who received 40 oncology drugs, finding significant survival benefits with a median life-years gained calculated at 0.38 years for overall survival and 0.80 years for progression-free survival.
  • The economic analysis revealed a total estimated value of quality-adjusted life years (QALY) gained of over $83 million, while the drug costs were about $97 million, highlighting the crucial role of PAPs in patient care and cost coverage.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!